NEW YORK (GenomeWeb News) – An exclusive agreement with NewBridge Pharmaceuticals will enable molecular diagnostics firm Genomic Health to expand the market for its flagship breast and colon cancer recurrence test Oncotype DX into Africa, the Middle East, and surrounding regions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.